Drug Profile
Research programme: Lyme disease therapy - Viral Genetics
Alternative Names: VGV-LLatest Information Update: 27 Feb 2023
Price :
$50
*
At a glance
- Originator Viral Genetics
- Developer VG Life Sciences
- Class Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lyme disease
Most Recent Events
- 27 Feb 2023 Discontinued - Preclinical for Lyme disease in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lyme-disease in USA (Parenteral)
- 30 Nov 2012 Viral Genetics is now called VG Life Sciences